Kavontae Smalls on Muck Rack

Kavontae Smalls

Verified
(He/Him)
Atlanta, Boston, Florida
As seen in: SurvivorNet, MSN, Yahoo News, Flipboard, Yahoo Sports, Yahoo, Atlanta Black Star, EIN News, GBH News (Boston, MA), NewsBreak, EIN Presswire and
Covers:  I cover a wide array of topics including but not limited to social justice, government, health news and technology.
2X Emmy Winner, Journalist, Producer, Podcast, Public Relations, Media Professional #NewsJunkie #PoliticalJunkie #WrestlingJunkie #AviationNerd #MediaRelations

Get in touch with Kavontae

Contact Kavontae, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Kavontae Smalls’s Biography

Read Full Bio →

Greetings,

I have a wide ranging career in television media and media relations and public relations. Given that I have been on the television news side, switched to the 'dark side' and returned to television, I have some perspective from multiple fronts.

My career has allowed me to serve in these capacities in some form over the years: TV Producer, Communications & Digital director, Public Information Officer, Public Relations Director, TV General Assignment Reporter, TV Multimedia Journalist,…

Kavontae Smalls’s Journalist Portfolio

Kavontae Smalls

Kavontae Smalls

Kavontae K. Smalls KavontaeSmalls@gmail.com

View article →

Articles

‘Practice-Changing’: FDA Approves Ibrance Combination as New Maintenance Option for HR+/HER2+ Metastatic Breast Cancer

|
By Kavontae Smalls Verified
| SurvivorNet Verified
Ibrance Combo Approved For HR+, HER2+ Metastatic Breast Cancer The FDA has approved targeted drug palbociclib (Ibrance) in combination with trastuzumab (Herceptin), and endocrine therapy, with or without pertuzumab (Perjeta), as a maintenance treatment for adults with a type of advanced breast cancer known as hormone receptor-positive (HR+), HER2-negative (HER2-).
Open in Who Shared Issue with article?

‘A Watershed Moment’: Revolution Medicines Chief Development Officer Dr. Alan Sandler On The Breakthrough Giving New Hope in Pancreatic Cancer

|
By Kavontae Smalls Verified
| SurvivorNet Verified
A Conversation With Revolution Medicines' Chief Development Officer In Chicago for the American Society of Clinical Oncology Annual Meeting, SurvivorNet sat down with Dr. Alan Sandler to discuss the excitement surrounding a potential new therapy for pancreatic cancer. It’s part of a new class of drugs that target the mutation behind 30% of all cancers, RAS mutations, which may be opening new possibilities for people facing some of the toughest diagnoses.
Open in Who Shared Issue with article?

Hopeful, Deeply Dedicated, & Investing In Hard-to-Treat Cancers: The View From Drugmaker Astellas’ Moitreyee Chatterjee-Kishore

|
By Kavontae Smalls Verified
| SurvivorNet Verified
Moving From Legacy Wins to New Frontiers in Cancer Care In Chicago for the annual gathering of leading oncologists, SurvivorNet sat down with Moitreyee Chatterjee‑Kishore, the Head of Oncology Development at Astellas, the global pharmaceutical giant that is investing heavily in next-generation cancer treatments. Moitreyee Chatterjee‑Kishore tells SurvivorNet the company is intentionally targeting areas of cancer drug development where patients urgently need better options.
Open in Who Shared Issue with article?
See all 567 articles

Interview

See all →

What was your first job as a journalist?

I produced morning drive segments for WRNE am radio soon after college.

Have you ever used a typewriter?

no

How is social media changing news?

Social media drives the news. In some respects, it's a good thing bc that's where the audience lives; however it shouldn't drive all news.
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified